Maria Eugenia Alonso-Ferrero
Immunogenicity Sciences Director Alexion Pharmaceuticals
Seminars
Thursday 26th February 2026
Advancing Lymphodepletion-Free CAR-Ts to Transform Autoimmune Disease Treatment
9:45 am
- Examine how lymphodepletion impacts trial design, patient safety, and overall therapeutic outcomes in autoimmune indications
- Explore strategies to improve monitoring, immunogenicity assessment, and product development for lymphodepletion-free CAR-Ts
- Highlight emerging approaches to optimise persistence and efficacy without reliance on toxic preconditioning regimens
